Sellas' long-delayed immunotherapy trial to end in failure

Sellas Life Sciences' experimental immunotherapy study, already delayed, is set to conclude without meeting its endpoints. The failure undermines the company's pipeline and raises questions about the viability of its approach. This is a company-specific setback with no immediate systemic market impact.